Ophthalmology

• Clinical Data

Pulsesight reports positive phase 1 data for PST611 in dry AMD

pharminent May 11, 2026

• M&A / Deals

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline

pharminent May 6, 2026

• M&A / Deals

Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout

pharminent May 6, 2026

• Clinical Data

Viridian data lift prospects for thyroid eye disease drug

pharminent May 5, 2026

• M&A / Deals

MSD-backed Ray locks in $125m to back eye drug pipeline

pharminent April 22, 2026

• Regulatory

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

pharminent April 15, 2026

• Commercial

Senju launches first-in-class dry eye disease drug in Japan

pharminent April 10, 2026

• Clinical Data

Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease

pharminent April 7, 2026

• Clinical Data

Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

pharminent April 7, 2026

• Clinical Data

Amgen scores with new thyroid eye disease formulation

pharminent April 7, 2026

• Clinical Data

Viridian tumbles on positive data for key eye drug prospect

pharminent March 31, 2026